drugset
drugset / Trial / NCT04630366

A Phase 1, First Time in Humans Study of NST-1024

NCT04630366 ↗

Phase 1 Completed 96 enrolled NorthSea Therapeutics B.V.
RandomizedParallel-groupTriple-blindTreatment

Summary

A first time in man study of NST-1024

Timeline

Start
2020-10-27
Primary completion
2022-06-20
Completion
2022-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject NST-1024 Unknown — Oral

Indications

hypertriglyceridemia